immunotherapy
Roche’s Tecentriq meets primary endpoint in Phase 3 bladder cancer trial
August 5, 2019Sales and Marketing Cancer, Roche, bladder cancer, immunotherapy, oncology, tecentriq
Roche has said its immunotherapy drug Tecentriq (Atezolizumab), when used in combination with platinum-based chemotherapy, significantly reduced the risk of …
Pfizer immune-oncology leader joins Aduro Biotech as new CMO
April 23, 2019Manufacturing and Production Aduro Biotech, Cancer, Pfizer, immuno-oncology, immunotherapy, oncology
Pfizer’s vice president and head of immune-oncology clinical development has joined Aduro Biotech as the company’s new Chief Medical Officer, …
Bowel cancers adjust themselves to hide from immunotherapies
April 15, 2019Sales and Marketing CEA, Cancer, bowel cancer, immunotherapy, oncology, tumour
Bowel cancers can avoid being caught by immunotherapy by ‘switching off’ a molecule on the surface of cells that is …
GSK buys Merck KGaA’s cancer immunotherapy for $4.2 billion
February 6, 2019Research and Development GSK, M7824, Merck, immunotherapy
British multinational GlaxoSmithKline has agreed to pay up to €3.7 billion ($4.2 billion) for the rights to Merck KGaA’s next …
Tumours with large number of mutations respond better to immunotherapies, study shows
January 15, 2019Manufacturing and Production, Research and Development Cancer, immunotherapy, nature, oncology, research, tumour
Tumours with a large number of DNA mutations are more likely to respond to immunotherapies than cancers with fewer mutations, …
Nobel Prize awarded to immuno-oncology innovators
October 2, 2018Manufacturing and Production Cancer, Nobel Prize, immunotherapy, kyoto, oncology, texas
The Nobel Prize for physiology or medicine has been awarded to both Professor James P Allison and Tasuku Honjo for …
Antibody therapy supresses HIV for months after treatment, study shows
October 1, 2018Sales and Marketing HIV, immunology, immunotherapy, nature, research
Researchers from the New York City based Rockefeller University have developed a novel immunotherapy, which is capable of suppressing HIV …
Roche’s Tecentriq/chemo combo smashes both co-primary endpoints at Phase 3
May 29, 2018Manufacturing and Production, Research and Development Cancer, NSCLC, Roche, immunotherapy, lung cancer, pharma, tecentriq
Roche has lifted the curtain on new Phase 3 data for its anti-PD-L1 cancer immunotherapy Tecentriq (atezolizumab), showing that the …
Lilly hires new leader of immuno-oncology
May 1, 2018Manufacturing and Production, Medical Communications Eli Lilly, biotech, drugs, immunoconlogy, immunotherapy, pharma, pharmaceutical
Immuno-oncology has become a huge area of the oncology market, led by the wave of PD-1/L1 drugs that are reaping …
AZ’s MedImmune signs $200m immuno-oncology partnership with Compugen
April 3, 2018Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Cancer, MedImmune, compugen, immunotherapy, oncology, pharma
AstraZeneca’s biologic R&D unit MedImmune is set to enter a partnership with Israeli drug firm Compugen to develop bi-specific and …
InSight Innovations to buy CureTech in $550m deal
March 28, 2018Research and Development, Sales and Marketing Cancer, CureTech, Insight Innovations, Pfizer, Teva, brain cancer, brain tumour, immunotherapy, israel
Israeli drug firm CureTech is be sold for the third time in four years, this time to InSight Innovations in …
NICE recommends Keytruda via CDF as first and only urothelial carcinoma immunotherapy
March 16, 2018Medical Communications, Sales and Marketing MSD, NICE, immunotherapy, keytruda, pharma
UK drugs watchdog NICE has published its finance guidance recommending the use of MSD’s Keytruda (pembrolizumab) on the NHS through …
Adaxis-AZ immunotherapy combo hit by clinical hold after death
March 13, 2018Manufacturing and Production, Research and Development Adaxis, AstraZeneca, Imfinzi, biotech, drugs, immunotherapy, pharma, pharmaceutical
Adaxis and AstraZeneca announced that they had agreed a combination program for axalimogene filolisbac and Imfinzi, respectively, back in 2014 …
Roche unveils strong combination treatment data in lung cancer
November 20, 2017Research and Development, Sales and Marketing Cancer, NSCLC< lung cancer, Roche, avastin, immunotherapy, pharma, tecentriq
Roche has unveiled new Phase 3 efficacy data which showed strong findings for its immunotherapy Tecentriq (atezolizumab) in combination with …
Gut bacteria may be key to efficacy of immunotherapies
November 6, 2017Research and Development, Sales and Marketing biotech, drugs, immunotherapy, pharma, pharmaceutical
Why immunotherapies are successful in some individuals and not in others is a matter of huge importance to both patients …
Latest content
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?
